Announced details
Treatment of pulmonary hypertension associated with chronic lung diseases, including COPD and ILD
The primary endpoint is the change from baseline in the 6-minute walk distance at 12 weeks after administration. Result figures: Not disclosed.
株式会社メドリープファーマ is responsible for development. Tatsumi Koichiro (巽浩一郎) has provided comments as a medical expert.
Emeritus Professor, Department of Respiratory Medicine, Chiba University School of Medicine. Other attributes: Not disclosed.
Head office of 株式会社メドリープファーマ: 3-3-1 Yaotome, Izumi-ku, Sendai, Miyagi
The impact on consolidated results for the fiscal year ending March 2027 (fiscal 2026) is minor.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Ferric maltol (development code: ST10) |
| Counterparty | Emeritus Professor, Department of Respiratory Medicine, Chiba University School of Medicine, Tatsumi Koichiro (巽浩一郎) (commenting as a medical expert) |
| Counterparty overview | Emeritus Professor, Department of Respiratory Medicine, Chiba University School of Medicine. Other attributes: Not disclosed. |
| Relationship with the Company | 株式会社メドリープファーマ is responsible for development. Tatsumi Koichiro (巽浩一郎) has provided comments as a medical expert. |
| Launch date | 9 November 2026 (date the domestic Phase 2 clinical trial commenced, actual) |
| Applicable area | Treatment of pulmonary hypertension associated with chronic lung diseases, including COPD and ILD |
| Location | Head office of 株式会社メドリープファーマ: 3-3-1 Yaotome, Izumi-ku, Sendai, Miyagi |
| Quantitative Effects | The primary endpoint is the change from baseline in the 6-minute walk distance at 12 weeks after administration. Result figures: Not disclosed. |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 (fiscal 2026) is minor. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The trial is being conducted as an exploratory study toward a Phase 3 trial, with the aim of adding an indication for pulmonary hypertension associated with chronic lung disease. The company positions this drug as a core pipeline product in the pulmonary hypertension field and aims to strengthen its earnings base and enhance corporate value over the medium to long term.